Cargando…
Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Hea...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199837/ https://www.ncbi.nlm.nih.gov/pubmed/25336979 http://dx.doi.org/10.2147/CEOR.S67888 |
_version_ | 1782339983595536384 |
---|---|
author | Bonafede, Machaon M Miller, Jeffrey D Laughlin-Tommaso, Shannon K Lukes, Andrea S Meyer, Nicole M Lenhart, Gregory M |
author_facet | Bonafede, Machaon M Miller, Jeffrey D Laughlin-Tommaso, Shannon K Lukes, Andrea S Meyer, Nicole M Lenhart, Gregory M |
author_sort | Bonafede, Machaon M |
collection | PubMed |
description | BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Health MarketScan(®) Medicaid Multi-State Database was used to identify Medicaid women aged 30–55 years with AUB who newly initiated GEA or hysterectomy (index event) during 2006–2010. Patients were required to have 12 months of continuous enrollment pre-index and post-index. Baseline characteristics were assessed in the pre-index period; health care utilization and costs (2011 USD), treatment complications, and reinterventions were assessed in the post-index period. RESULTS: Of 1,880 women who met the study criteria (mean age 40.7 years), 53.4% were Caucasian, 33.1% were African-American, and 2.3% were Hispanic; many (42.8%) received their Medicaid eligibility due to disability. Similar proportions received GEA (50.9%) or hysterectomy (49.1%). At baseline, both groups also had similar Deyo-Charlson Comorbidity scores (0.65), and use of antibiotics (69.4%), nonsteroidal anti-inflammatory drugs (56.3%), and oral contraceptives (5.3%). More hysterectomy patients than GEA patients had a treatment-related complication (52% versus 36%, respectively, P<0.001). Initial treatment costs were higher for hysterectomy ($11,270) than for GEA ($3,958, P<0.001); monthly gynecology-related costs in the remainder of the year were not significantly different for hysterectomy ($63) and GEA ($16, P=0.11). CONCLUSION: Hysterectomy was nearly three times more costly than GEA for initial treatment of AUB, and associated with more treatment-related complications. These results may be informative in the context of new federal mandates for Medicaid expansion, which are likely to focus on cost savings through use of outpatient treatments such as GEA. |
format | Online Article Text |
id | pubmed-4199837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41998372014-10-21 Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs Bonafede, Machaon M Miller, Jeffrey D Laughlin-Tommaso, Shannon K Lukes, Andrea S Meyer, Nicole M Lenhart, Gregory M Clinicoecon Outcomes Res Original Research BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Health MarketScan(®) Medicaid Multi-State Database was used to identify Medicaid women aged 30–55 years with AUB who newly initiated GEA or hysterectomy (index event) during 2006–2010. Patients were required to have 12 months of continuous enrollment pre-index and post-index. Baseline characteristics were assessed in the pre-index period; health care utilization and costs (2011 USD), treatment complications, and reinterventions were assessed in the post-index period. RESULTS: Of 1,880 women who met the study criteria (mean age 40.7 years), 53.4% were Caucasian, 33.1% were African-American, and 2.3% were Hispanic; many (42.8%) received their Medicaid eligibility due to disability. Similar proportions received GEA (50.9%) or hysterectomy (49.1%). At baseline, both groups also had similar Deyo-Charlson Comorbidity scores (0.65), and use of antibiotics (69.4%), nonsteroidal anti-inflammatory drugs (56.3%), and oral contraceptives (5.3%). More hysterectomy patients than GEA patients had a treatment-related complication (52% versus 36%, respectively, P<0.001). Initial treatment costs were higher for hysterectomy ($11,270) than for GEA ($3,958, P<0.001); monthly gynecology-related costs in the remainder of the year were not significantly different for hysterectomy ($63) and GEA ($16, P=0.11). CONCLUSION: Hysterectomy was nearly three times more costly than GEA for initial treatment of AUB, and associated with more treatment-related complications. These results may be informative in the context of new federal mandates for Medicaid expansion, which are likely to focus on cost savings through use of outpatient treatments such as GEA. Dove Medical Press 2014-10-08 /pmc/articles/PMC4199837/ /pubmed/25336979 http://dx.doi.org/10.2147/CEOR.S67888 Text en © 2014 Bonafede et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Bonafede, Machaon M Miller, Jeffrey D Laughlin-Tommaso, Shannon K Lukes, Andrea S Meyer, Nicole M Lenhart, Gregory M Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title | Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title_full | Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title_fullStr | Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title_full_unstemmed | Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title_short | Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs |
title_sort | retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in us medicaid programs |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199837/ https://www.ncbi.nlm.nih.gov/pubmed/25336979 http://dx.doi.org/10.2147/CEOR.S67888 |
work_keys_str_mv | AT bonafedemachaonm retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms AT millerjeffreyd retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms AT laughlintommasoshannonk retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms AT lukesandreas retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms AT meyernicolem retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms AT lenhartgregorym retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms |